[
{
	"page":"ENAS5098_1.0.0.0",
	"text":"Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth de Vries, Alan Horwich, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5):V1-27 http://annonc.oxfordjournals.org/content/27/suppl_5/v1.full.pdf+html Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 ESMO Guidelines Committee Ann Oncol 2017; 28(Suppl 4): iv158–61 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv158/18564105/mdx245.pdf Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 ESMO Guidelines Committee Ann Oncol 2017; 28(Suppl 4): iv162–4 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv162/18564107/mdx246.pdf 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S and Panel Members Ann Oncol 2014;25:1475-84 http://annonc.oxfordjournals.org/content/25/8/1475.full.pdf+html 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Eberhard WEE, De Ruysscher D, Weder W, Le Pechoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S and Panel Members Ann Oncol 2015;26:1573-88 http://annonc.oxfordjournals.org/content/26/8/1573.full.pdf+html 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E and Panel Members Ann Oncol 2014;25:1462-74 http://annonc.oxfordjournals.org/content/25/8/1462.full.pdf+html Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv1–21 https://​academic.oup.com/​annonc/​article-​pdf/​28/​suppl_4/​iv1/​18528229/​mdx222.pdf 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O’Byrne K, Stahel R, Peters S, Felip E and Panel Members Ann Oncol 2014;25:1681-90 http://annonc.oxfordjournals.org/content/25/9/1681.full.pdf+html Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Früh M, De Ruysscher D, Popat S, Crinò Peters S and Felip E, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi99-105 https://​academic.oup.com/​annonc/​article-pdf/​24/​suppl_6/​vi99/​160407/​mdt178.pdf Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Baas P, Fennell D, Kerr K, Van Schil PE, Haas RL and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(suppl 5):v31-9 https://​academic.oup.com/​annonc/​article-​pdf/​26/​suppl_5/​v31/​6675007/​mdv199.pdf Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Girard N, Ruffini E, Marx A, Faivre-Finn C and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(suppl 5):v40-55 https://​academic.oup.com/​annonc/​article-pdf/​26/​suppl_5/​v40/​6675418/​mdv277.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) and consensus statements on the management of lung cancers (early-stage, locally advanced and metastatic non-small-cell lung cancer [NSCLC], and small-cell lung cancer [SCLC] and chest tumours (malignant pleural mesothelioma and thymic epithelial tumours). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs and consensus statements on lung & chest tumours are intended to provide you with a set of recommendations for the best standards of care for lung & chest tumours, using evidence-based medicine. Implementation of ESMO CPGs and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-based management of lung & chest tumours. Please visit http://www.esmo.org or http://www.oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5098_2.0.0.0",
	"text":"Diagnosis Thymic epithelial tumours are classified according to the World Health Organization (WHO) histopathological classification system Thymomas are sub-‍divided into A, AB, B1, B2, B3 and rare others based on the morphology of epithelial tumour cells, the relative proportion of the non-tumoural lymphocytic component and resemblance to normal thymic architecture The term ‘benign thymoma&#39; should be avoided Thymic carcinomas are similar to their extrathymic counterparts, the most frequent sub-‍type being squamous cell carcinoma Genetic risk factors, such as multiple endocrine neoplasia 1 gene (MEN1), may participate in the development of thymomas and thymic carcinoids and oncogenetic assessment is recommended in case of familial thymic tumours Diagnosis relies on differentiating between a thymic epithelial tumour and other anterior mediastinal tumours and non-‍malignant thymic lesions Standard imaging is with intravenous (IV) contrast-‍enhanced computed tomography (CT) scan of the thorax, with exploration of the mediastinum and pleura Magnetic resonance imaging (MRI) can be used in difficult cases to differentiate tumours from hyperplasia when a CT scan is doubtful or for cystic lesions Fluorodeoxyglucose positron emission tomography (FDG-PET) is generally not recommended to assess thymic masses PET is optional for tumours with aggressive histology and at an advanced stage to complete the staging work-‍up A complete history, full clinical examination (including neurological assessments) and systematic immunological check-‍up, including complete blood cell counts with reticulocytes and serum protein electrophoresis and tests for anti-‍acetylcholine receptor and anti-‍nuclear antibodies, is recommended Thymoma is the most likely diagnosis when facing a mediastinal mass associated with autoimmune disease, as shown here, while thymic carcinoma patients typically have unspecific local symptoms Pre-‍treatment biopsy is not required if the diagnosis of a thymic tumour is highly suspected and upfront surgical resection is achievable Biopsy is required in all other clinical situations, with percutaneous core needle biopsy or incisional surgical biopsy through mediastinotomy or mini-‍thoracotomy as possible options Deep, multiple biopsies are preferred to wide, scant biopsies Fine-‍needle aspiration is generally not recommended Although designed for surgical resection specimens, the WHO classification system may be used for small biopsies Immunohistochemistry (IHC) may be helpful and anti-‍CD117 (KIT) and anti-‍CD5 expression can assist in establishing the thymic origin in approximately 80% of mediastinal carcinomas In thymic tumours with more than one histological pattern, each component should be listed and quantified in 10% increments; a thymic carcinoma component should be mentioned first For difficult cases, a second pathologist should be consulted or the case referred to a thymic tumour pathology panel"
},
{
	"page":"ENAS5098_3.0.0.0",
	"text":"Autoimmune disorders asso. with thymoma AUTOIMMUNE DISORDERS ASSOCIATED WITH THYMOMA Neuromuscular Myasthenia gravis Myotonic dystrophy Limbic encephalitis Peripheral neuropathy Autonomic neuropathy Acquired neuromyotonia Morvan syndrome (neuromyotonia and encephalitis) Stiff person syndrome Cerebellar degeneration Polymyositis (carcinomas) Haematological disorders Red cell aplasia Pernicious anaemia Erythrocytosis Pancytopaenia Haemolytic anaemia Leukaemia Multiple myeloma Collagen and autoimmune disorders Systemic lupus erythematosus Rheumatoid arthritis Sjogren&#39;s syndrome Scleroderma Interstitial pneumonitis Immune deficiency disorders Hypogammaglobulinaemia (Good syndrome) T cell deficiency syndrome Endocrine disorders Multiple endocrine neoplasia Cushing&#39;s syndrome Thyroiditis Dermatological disorders Pemphigus Lichen planus Chronic mucosal candidiasis Alopecia areata Miscellaneous Giant cell myocarditis Nephrotic syndrome Ulcerative colitis Hypertrophic osteoarthropathy"
},
{
	"page":"ENAS5098_4.1.0.0",
	"text":"Staging and risk assessment Overview Thymic tumours are routinely staged with the Masaoka-‍Koga staging system, as shown here, a surgical pathology system that is assessable only after surgical resection of the tumour A tumour node metastasis (TNM)-‍based staging system for thymic malignancies, proposed by the International Association for the Study of Lung Cancer (IASLC) Staging Prognostic Factors Committee and the International Thymic Malignancy Interest Group (ITMIG), is incorporated into the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system of thoracic malignancies The 8th edition of the TNM staging system has been officially accepted by the UICC and AJCC and globally implemented in 2017; of note, the AJCC has delayed its implementation until 2018 Assessment of tumour resectability is based mainly on the surgeon&#39;s expertise, but discussions of indications for surgery within a multidisciplinary tumour board setting are recommended Complete resection (R0, resection with negative margins) is generally achievable in Masaoka-‍Koga stage I/II and some stage III tumours The new TNM staging may help to formalise resectability criteria, as shown here Autoimmune disorders may cause death in 25% of thymomas and the management of such syndromes should be integrated into oncological treatment"
},
{
	"page":"ENAS5098_4.2.0.0",
	"text":"  MASAOKA-‍KOGA,1994 INTERNATIONAL THYMIC MALIGNANCY INTEREST GROUP, 2011* 10-YEAR OVERALL SURVIVAL 10-YEAR CUMULATIVE INCIDENCE OF RECURRENCE THYMOMA THYMIC CARCINOMA Stage I Stage IIA Stage IIB Stage III Stage IVA Stage IVB   Grossly and microscopically completely encapsulated tumour   Invasion into but not through the capsule   84% (81–86%)           In the absence of capsule, absence of invasion into surrounding tissues   Microscopic transcapsular invasion   Microscopic transcapsular invasion (less than 3 mm)       8% (7–8%)   25% (22–29%)   Macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent to but not breaking through the mediastinal pleura or pericardium   Gross extension into normal thymus or perithymic fat surrounding the tumour (microscopically confirmed)   83% (79–87%)           Adherence to pleura or pericardium, with microscopic confirmation of perithymic invasion   Macroscopic invasion into neighbouring organ (i.e., pericardium, great vessel, or lung)   Microscopic invasion of the mediastinal pleura (either partial or penetrating the elastin layer)   70% (64–75%)   29% (27–31%)   59% (44–76%)   Microscopic invasion of the pericardium (either partial in the fibrous layer or penetrating through to the serosal layer) Microscopically confirmed direct penetration into the outer elastin layer of the visceral pleura or into the lung parenchyma Invasion into the phrenic or vagus nerves (microscopically confirmed) Invasion into or penetration through major vascular structures (microscopically confirmed) Adherence (i.e. fibrous attachment) of lung or adjacent organs only if there is mediastinal pleural or pericardial invasion (microscopically confirmed) Pleural or pericardial metastasis Microscopically confirmed separate nodules in the visceral or parietal pleural, pericardial or epicardial surfaces 42% (26–58%) 71% (34–100%) 76% (58–100%) Lymphogenous or haematogenous metastasis Lymphogenous or haematogenous metastasis 53% (32–73%) 57% (24–90%) 54% (37–67%) *Refinement to original staging system Information reprinted from Detterbeck F, et al. J Thorac Oncol 2011;6:S1710–6, with permission from Elsevier."
},
{
	"page":"ENAS5098_4.3.0.0",
	"text":"TNM staging Stage Descriptors T- Primary Tumour Tx Primary tumour cannot be assessed T0 No evidence of primary tumour T1 Tumour encapsulated or extending into the mediastinal fat, may involve the mediastinal pleura   T1a No mediastinal pleural involvement T1b Direct invasion of the mediastinal pleura T2 Direct invasion of the pericardium (partial or full-thickness) T3 Direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall or extrapericardial pulmonary artery or vein T4 Direct invasion into any of the following: aorta (ascending, arch or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, or oesophagus N - Regional Lymph Nodes NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in anterior (perithymic) lymph nodes N2 Metastasis in deep intrathoracic or cervical lymph nodes Metastasis M0 No pleural, pericardial or distant metastasis M1 Distant metastasis   M1a Separate pleural or pericardial nodule(s) M1b Distant metastasis beyond the pleura or pericardium Stage grouping Corresponding Masaoka-‍Koga stage I T1 N0 M0 I, IIA, IIB, III II T2 N0 M0 III IIIA T3 N0 M0 III IIIB T4 N0 M0 III IVA Any T N1 M0 Any T N0,1 M1a IVA IVB IVB Any T N2 M0,1a Any T Any N IVB M1b TNM, tumour node metastasis Brierley JD et al (eds). TNM Classification of Malignant Tumours, 8th edition: John Wiley & Sons, Inc., Oxford, 2016. Reprinted with permission from John Wiley & Sons, Inc."
},
{
	"page":"ENAS5098_2018032044",
	"text":"Treatment, as shown in the figures here and table here, is based on the resectability of the tumour"
},
{
	"page":"ENAS5098_5.2.0.0",
	"text":"Stage-‍matched therapeutic strategies See the table below for recommended chemotherapy regimens and radiotherapy doses/‍schedules Masaoka-‍Koga Stage Thymoma Thymic carcinoma Stage I Upfront surgery No biopsy If R0: no postoperative RT If R1: postoperative RT (50–54 Gy) Upfront surgery No biopsy If R0: consider postoperative RT (45–50 Gy) If R1: postoperative RT (50–54 Gy) Stage IIA Upfront surgery No biopsy If R0: - Type A–B2: no postoperative RT - Type B3: consider postoperative RT (45–50 Gy) If R1: postoperative RT (50–54 Gy) Upfront surgery No biopsy If R0: Consider postoperative RT (45–50 Gy) If R1: - Postoperative RT (50–54 Gy) - Consider postoperative chemotherapy Stage IIB Upfront surgery No biopsy If R0: - Type A–B1: no postoperative RT - Type B2–B3: consider postoperative RT (45–50 Gy) If R1: postoperative RT (50–54 Gy) Upfront surgery No biopsy If R0: Consider postoperative RT (45–50 Gy) If R1: - Postoperative RT (50–54 Gy) - Consider postoperative chemotherapy Stage III–IVA Resectable tumour (TNM I–IIIA, i.e. T1–3): - Upfront surgery - Postoperative RT (45–50 Gy), with boost on areas of concern Unresectable tumour (TNM IIIA–B, i.e. T3–T4): - Biopsy - Primary chemotherapy (preferably anthracycline-‍based) - If the tumour becomes resectable: - Surgery - Postoperative RT (45–50 Gy), with boost on areas of concern (R0, R1 resection) - If the tumour remains unresectable or R2: - Definitive RT (60 Gy) - Option: chemoradiotherapy - Option: concurrent chemoradiotherapy (platin and etoposide, 60 Gy) Resectable tumour (TNM I–IIIA, i.e. T1–3): - Upfront surgery - Postoperative RT (40–50 Gy), with boost on areas of concern - Consider postoperative chemotherapy Unresectable tumour (TNM IIIA–B, i.e. T3–T4): - Biopsy - Primary chemotherapy (preferably anthracycline-‍based) - If the tumour becomes resectable: - Surgery - Postoperative RT (45–50 Gy), with boost on areas of concern (R0, R1 resection) - Consider postoperative chemotherapy (R0, R1 resection) - If the tumour remains unresectable or R2: - Definitive RT (60 Gy) - Option: chemoradiotherapy - Option: concurrent chemoradiotherapy (platin and etoposide, 60 Gy) Stage IVB Definitive chemotherapy - If the tumour becomes resectable, consider: - Surgery and postoperative RT - Definitive RT Definitive chemotherapy R0, resection with negative margins; R1, microscopically incomplete resection; R2, macroscopically incomplete resection; RT, radiotherapy; TNM tumour node metastasis"
},
{
	"page":"ENAS5098_2017032440",
	"text":"Surgery is the first choice if R0 resection is deemed to be achievable upfront, possibly followed by postoperative radiotherapy (RT) and, less frequently, chemotherapy"
},
{
	"page":"ENAS5098_5.4.0.0",
	"text":"Surgery The standard approach is median sternotomy Complete thymectomy, including the tumour, residual thymus gland and perithymic fat, is generally preferred to avoid the risk of local recurrences when part of the thymus gland is left behind Thymomectomy, leaving residual thymic tissue and perithymic fat behind, is an option in stage I tumours in non-‍myasthenic patients For widely invasive, stage III/‍IV tumours, removal en bloc of all affected structures, including lung, parenchyma, pericardium, great vessels, nerves and pleural implants, should be carried out Areas of uncertain resection margins should be marked with clips to allow precise delivery of postoperative RT Phrenic nerve preservation does not affect overall survival but increases the risk of local recurrence and should be balanced with the achievement of an R0 resection Frozen sections for the assessment of resection margin tumour involvement are not recommended given the high risk of false negative results Minimally invasive surgery is an option for presumed stage I and possibly stage II tumours in the hands of appropriately trained surgeons but should not jeopardise the achievement of R0 resection, which may ultimately require switching to an open procedure It is not recommended for stage III tumours due to the absence of long-‍term follow-‍up data The IASLC/‍ITMIG TNM staging system recommends locoregional lymphadenectomy during resection for all thymic tumour types Systematic lymphadenectomy (N1+N2) is strongly recommended for thymic carcinoma due to the high rate of lymphatic spread (20% vs 3% in thymomas) Routine removal of anterior mediastinal nodes and anterior cervical nodes is recommended Systematic sampling of other intrathoracic sites is encouraged in stage III/‍IV tumours Surgeon and pathologist input is required for the accurate staging of tumours; the correct presentation of the pathological specimen is the surgeon&#39;s responsibility Given the potential heterogeneity of tumours, at least five sections with one additional block for each additional cm should be examined; if the margin is <1 mm, at least three additional sections through this area should be obtained Completeness of resection should be assessed, making the distinction between tissues that have been cut or dissected, and a surface bounded by a space, which should not be designated as a positive margin"
},
{
	"page":"ENAS5098_5.5.0.0",
	"text":"Post-‍operative radiotherapy Stage and completeness of resection, followed by histology, are the most relevant criteria in assessing the value of postoperative RT 3D conformal RT or intensity modulated RT (IMRT) targeted to the tumour bed, with a clinical target volume including the whole thymic space, the tumour and its extensions and the anterior, superior and middle mediastinum is recommended The optimal dose/‍schedule has yet to be defined, but a total dose of 45–50 Gy after R0 resection and 50–54 Gy after microscopically incomplete (R1) resection, with a boost to areas of likely residual disease, using a conventional fractionation scheme of 1.8–2 Gy/‍day over a 4–6-week period is suggested The field may encompass involved nodes and the site of a resected pleural implant Post-‍operative RT should start within 3 months of surgery Prophylactic irradiation of supraclavicular nodes and low-‍dose entire hemithoracic RT are not recommended Postoperative RT is not indicated after R0 resection of Masaoka-‍Koga stage I tumours. It may be considered in stage II thymomas in case of aggressive histology (B2, B3) or extensive transcapsular invasion (stage IIB) Postoperative RT is recommended after R0 resection of stage III/‍IVA thymomas in an effort to prolong relapse-‍free and overall survival After R0 resection of thymic carcinomas, postoperative RT is optional for stage I tumours, should be considered for stage II tumours and is recommended for stage III/‍IVA tumours Postoperative RT is also recommended following R1 or macroscopically incomplete (R2) thymic tumour resection, to a total dose of 50–54 Gy and 60 Gy, respectively, with a 10 Gy boost to areas of likely residual disease"
},
{
	"page":"ENAS5098_5.6.0.0",
	"text":"Post-‍operative chemotherapy Postoperative chemotherapy is not recommended after R0–R1 resection of thymomas but may be considered for stage II/‍III/‍IV thymic carcinomas, especially if not delivered as induction treatment"
},
{
	"page":"ENAS5098_5.7.0.0",
	"text":"Advanced disease If R0 resection is not likely to be achieved upfront on the basis of imaging studies, a biopsy should be performed, followed by primary/‍induction chemotherapy as part of a curative-‍intent sequential strategy that integrates subsequent surgery or RT Patients not eligible for local treatment should receive palliative chemotherapy alone"
},
{
	"page":"ENAS5098_2017032439",
	"text":"Cisplatin-‍based regimens should be administered, as shown here, and combinations of cisplatin, doxorubicin and cyclophosphamide (CAP) or cisplatin and etoposide (PE) are recommended options Primary chemoradiotherapy with PE is an option for thymic carcinomas Usually, 2–4 cycles are administered prior to imaging to assess tumour resectability Surgery should be offered when R0 resection is deemed achievable; extended resection may be required Hyperthermic intrapleural chemotherapy and extra-‍pleural pneumonectomy, followed by postoperative RT, may be discussed for stage IVA tumours Sub-‍total, or debulking, resection is an option for selected cases of thymoma with the aim of facilitating subsequent definitive RT Debulking resection is not recommended for thymic carcinomas Postoperative chemoradiotherapy (PE plus RT at a total dose of 60 Gy in 30 fractions) may be considered after debulking/R2 resection"
},
{
	"page":"ENAS5098_5.9.0.0",
	"text":"Definitive radiotherapy Definitive RT is recommended as part of a sequential chemoradiotherapy strategy for patients deemed to be poor surgical candidates, either because R0 resection is unlikely or because the patient has poor performance status or co-‍existing medical conditions Combination with PE chemotherapy may be considered"
},
{
	"page":"ENAS5098_5.10.0.0",
	"text":"Definitive chemotherapy Single modality cisplatin-‍based combination chemotherapy should be offered for the relief of tumour-‍related symptoms to patients with advanced, unresectable, non-‍irradiable or metastatic (stage IVB) thymic epithelial tumours CAP is the preferred regimen, with carboplatin and paclitaxel (Carbo-‍Px) as an option for thymic carcinomas Surgery or RT can be used in rare, selected cases of metastatic thymoma, although benefits on outcome are not proven Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy"
},
{
	"page":"ENAS5098_5.11.0.0",
	"text":"Recurrences Recurrences are not uncommon (10–15% of all-‍stage resected tumours) and should be managed according to the same strategy as newly diagnosed tumours R0 resection of recurrent lesions is a major predictor of favourable outcomes and is recommended for resectable recurrences For unresectable recurrences, several consecutive lines of chemotherapy may be administered and the use of a previously effective regimen should be considered Cardiac toxicity is increased in patients previously receiving mediastinal RT Preferred second-‍line chemotherapy regimens include Carbo-‍Px and PE, with capecitabine and gemcitabine (Cap-‍GEM) as an option Subsequent-‍line options include pemetrexed and oral etoposide Patients with octreoscan-‍positive thymoma, not eligible for chemotherapy, may benefit from octreotide ± prednisone"
},
{
	"page":"ENAS5098_5.12.0.0",
	"text":"Chemotherapy regimens for advanced TETs Regimen Agents Doses ADOC Doxorubicin 40 mg/m2 / 3w Cisplatin 50 mg/m2 / 3w Vincristine 0.6 mg/m2 / 3w Cyclophosphamide 700 mg/m2 / 3w CAP Cisplatin 50 mg/m2 / 3w Doxorubicin 50 mg/m2 / 3w Cyclophosphamide 500 mg/m2 / 3w PE Cisplatin 60 mg/m2 / 3w Etoposide 120 mg/m2 x 3 / 3w VIP Etoposide 75 mg/m2 x 4d / 3w Ifosfamide 1.2 g/m2 x 4d / 3w Cisplatin 20 mg/m2 x 4d / 3w CODE Cisplatin 25 mg/m2 / 1w Vincristine 1 mg/m2 / 2w Doxorubicin 40 mg/m2 / 2w Etoposide 80 mg/m2 x 3 / 2w Carbo-‍Px Carboplatin AUC 5–6 / 3w Paclitaxel 200–225 mg/m2 / 3w Cap-‍GEM Capecitabine 650 mg/m2 bid d1-14 / 3w Gemcitabine 1000 mg/m2 d1, d8 / 3w AUC, area under the curve; bid, twice a day; d, day; w, week Girard N. Expert Rev Anticancer Ther 2012;12:685-95 Adapted with permission of Taylor & Francis Ltd"
},
{
	"page":"ENAS5098_6.0.0.0",
	"text":"Personalised medicine Personalised medicine approaches are limited by the availability of validated molecular markers with prognostic or predictive value KIT sequencing (exons 9–17) is an option for refractory thymic carcinomas to assess suitability for tyrosine kinase inhibitor treatment, particularly in clinical trials Imatinib should not be administered in the absence of KIT sensitising mutations, as it has no activity in this setting The angiogenesis inhibitor, sunitinib, is a second-‍line treatment option for thymic carcinomas, independent of KIT mutation status The mechanistic target of rapamycin (mTOR) inhibitor, everolimus, is an option for refractory tumours NB: imatinib, sunitinib and everolimus do not have regulatory approval for use in thymic malignancies"
},
{
	"page":"ENAS5098_7.0.0.0",
	"text":"Follow-‍up In the absence of prospective data, follow-‍up recommendations are based on expert consensus and recurrence data Baseline thoracic CT scans should be conducted 3–4 months after surgery For R0 resected stage I/II thymomas, CT scans annually for 5 years then every 2 years are recommended For stage III/‍IV thymomas, thymic carcinoma or after R1–2 resection, CT scans every 6 months for 2 years, then annually thereafter, are recommended Follow-‍up should be continued for 10–15 years Patients with clinical myasthenia gravis should be educated about the risks of myasthenic crisis in certain situations, such as stress or following the administration of some drugs Participation in collaborative research initiatives and clinical trials, when available, is recommended"
},
{
	"page":"ENAS5098_8.1.0.0",
	"text":"Thymic epithelial tumours are classified according to the WHO histopathologic classification, which may be used for small biopsies Oncogenetic assessment, with a particular focus on MEN1, should be conducted Differential diagnosis with other anterior mediastinal tumours and non-‍malignant lesions is key Standard imaging is IV contrast-‍enhanced CT of the thorax [IV, A] MRI is recommended to differentiate tumours from hyperplasia when a CT scan is doubtful or for cystic lesions [IV, B] FDG-‍PET is generally not recommended to assess thymic masses [IV, C] A complete history, full clinical examination and systematic immunological check-‍up, including complete blood cell counts, with reticulocytes and serum protein electrophoresis and anti-‍acetylcholine receptor and antinuclear antibodies tests, is recommended [V, A] Thymoma is the first diagnosis to consider when facing a mediastinal mass associated with autoimmune disease Pre-‍treatment biopsy is not required if the diagnosis of thymic epithelial tumour is highly suspected and upfront surgical resection is achievable [IV, E] Biopsy, for example using percutaneous core-‍needle biopsy or incisional surgical biopsy, is required in all other clinical situations [IV, A]; fine-‍needle aspiration is not recommended [IV, D] IHC with anti-‍CD117 (KIT) and anti-‍CD5 antibodies is useful to establish the thymic primary nature of a mediastinal carcinoma [V, A] Each component of heterogeneous tumours may be quantified in 10% increments [V, C] Consultation with a second pathologist or referral to a thymic tumour pathology panel is recommended in difficult cases"
},
{
	"page":"ENAS5098_8.2.0.0",
	"text":"Staging and risk assessment The 8th edition of the TNM staging system has been officially accepted by the UICC and AJCC and globally implemented in 2017; of note, the AJCC has delayed its implementation until 2018 Assessment of resectability is at the surgeon’s discretion, but multidisciplinary tumour board input is recommended [V, B] Autoimmune syndrome treatment should be integrated into oncological treatment of thymomas, where appropriate [V, A]"
},
{
	"page":"ENAS5098_2018032045",
	"text":"Treatment strategies are based primarily on the possibility of upfront tumour resection [IV, A]"
},
{
	"page":"ENAS5098_2017032442",
	"text":"Surgery is the first choice where R0 resection is achievable upfront [IV, A]"
},
{
	"page":"ENAS5098_8.3.2.0",
	"text":"Surgery The standard approach is median sternotomy [IV, A] Complete thymectomy, including the tumour, the residual thymus gland and perithymic fat, is preferred [IV, B] Thymomectomy alone is an option in stage I tumours in non-‍myasthenic patients [IV, C] For extensive invasive tumours (stage III/‍IV), removal en bloc of all affected structures, including lung parenchyma, pericardium, venous great vessels, nerves and pleural implants, should be carried out [IV, A] Areas of uncertain margins should be marked with clips to allow precise delivery of postoperative RT [IV, B] Phrenic nerve preservation increases the risk of local recurrence [IV, C] Frozen sections to assess resection margin tumour involvement are not recommended Minimally invasive surgery is an option for stage I–II tumours [IV, C] but is not recommended for stage III tumours [IV, D] Systematic lymphadenectomy (N1 + N2) is strongly recommended for thymic carcinomas [V, B] Routine removal of anterior mediastinal and anterior cervical nodes is recommended [IV, A] Systematic sampling of intrathoracic sites is encouraged in stage III/‍IV tumours [V, B] Communication between surgeons and pathologists is required for accurate tumour staging [V, A] At least five representative sections should be examined; if the margin is <1 mm, at least three additional sections through this area should be obtained [V, B] Completeness of resection should be assessed, making the distinction between tissues that have been cut or dissected, and a surface bounded by a space, which should not be designated as a positive margin [V, A]"
},
{
	"page":"ENAS5098_8.3.3.0",
	"text":"Post-‍operative radiotherapy Stage and completeness of resection are the most relevant criteria in the consideration of postoperative RT (3D conformal RT or IMRT targeted to the tumour bed [IV, A]), which should start within 3 months of surgery [V, B] Clinical target volume includes the whole thymic space, the tumour and its extensions and the anterior, superior and middle mediastinum [IV, A] Recommended RT doses are: total dose 45–50 Gy after R0 resection and 50–54 Gy after R1 resection, using conventional fractionation (1.8–2 Gy/‍day over 4–6 weeks), with a boost to areas of likely residual disease [IV, B] The field may encompass involved nodes [IV, B] and the site of a resected pleural implant [V, C] Prophylactic irradiation of supraclavicular nodes [V, E] and low-‍dose entire hemithoracic RT [IV, C] are not recommended After R0 thymoma resection, postoperative RT is not indicated for Masaoka-‍Koga stage I [II, E] or II [IV, C] disease but may be considered in case of aggressive histology for stage IIA (type B2, B3) or stage IIB disease [IV, C] and is recommended for stage III/‍IVA disease [IV, B] After R0 thymic carcinoma resection, postoperative RT is optional for stage I tumours [V, C], should be considered for stage II tumours [IV, B] and is recommended for stage III/‍IVA tumours [IV, B] Postoperative RT is recommended for R1 or R2 resected tumours [IV, B] (to a total dose of 50-54 Gy and 60 Gy, respectively, with a 10 Gy boost to areas of likely residual disease)"
},
{
	"page":"ENAS5098_8.3.4.0",
	"text":"Post-‍operative chemotherapy Postoperative chemotherapy is not recommended after R0–R1 thymoma resection [III, E] but may be considered for stage II/‍III/‍IV thymic carcinomas"
},
{
	"page":"ENAS5098_2017032443",
	"text":"When R0 resection is not achievable upfront, a biopsy should be followed by primary/‍induction chemotherapy and subsequent surgery or RT Patients not eligible for local treatment receive palliative chemotherapy alone"
},
{
	"page":"ENAS5098_8.3.6.0",
	"text":"Primary/‍induction chemotherapy Cisplatin-‍based combinations (CAP or PE) are recommended [III, A] Primary chemoradiotherapy with PE is an option for thymic carcinomas [III, B] Usually, 2–4 cycles are administered before imaging to reassess resectability of the tumour [III, A] Surgery should be offered when R0 resection is deemed achievable [III, A] Hyperthermic intrapleural chemotherapy and extra-‍pleural pneumonectomy, followed by RT, may be discussed for stage IVA tumours [IV, C] Sub-‍total (debulking) resection is an option in selected thymoma cases [IV, C] but is not recommended for thymic carcinomas [V, D] Postoperative chemoradiotherapy (PE plus RT at a total dose of 60 Gy in 30 fractions) may be considered after debulking/R2 resection [IV, B]"
},
{
	"page":"ENAS5098_8.3.7.0",
	"text":"Definitive radiotherapy Definitive RT is recommended for poor surgical candidates as part of sequential chemoradiotherapy [III, A] Combination with PE chemotherapy may be considered [V, C]"
},
{
	"page":"ENAS5098_8.3.8.0",
	"text":"Definitive chemotherapy Cisplatin-‍based combination regimens should be offered for advanced, unresectable, non-‍irradiable or stage IVB tumours [III, A] CAP is the preferred regimen [III, B], with Carbo-‍Px as an option for thymic carcinomas [III, B] Surgery or RT has no proven outcome benefit [IV, C] RECIST v1.1 criteria should be used to assess response [V, A]"
},
{
	"page":"ENAS5098_8.3.9.0",
	"text":"Recurrences Recurrences should be managed with the same strategies as newly diagnosed tumours [IV, A] Complete resection of recurrent lesions is recommended For non-‍resectable recurrences, consecutive lines of chemotherapy may be administered following tumour progression and use of a previously effective regimen should be considered [IV, B] Preferred regimens for second-‍line treatment include Carbo-‍Px and PE [III, B]; Cap-‍GEM is also an option [III, B] Subsequent-‍line options include pemetrexed [III, B] and oral etoposide In patients with octreoscan-‍positive thymoma not eligible to receive additional chemotherapy, octreotide ± prednisone may be an option [III, B]"
},
{
	"page":"ENAS5098_8.4.0.0",
	"text":"Personalised medicine KIT sequencing (exons 9–17) to assess suitability for specific inhibitor treatment is an option for refractory thymic carcinomas, particularly in the context of clinical trials [IV, B] Imatinib should not be administered in the absence of a KIT sensitising mutation [III, E] Sunitinib can be used second line for thymic carcinomas, independent of KIT status [III, A] Everolimus may be an option for refractory tumours [III, B] NB: imatinib, sunitinib and everolimus do not have regulatory approval for use in thymic malignancies"
},
{
	"page":"ENAS5098_8.5.0.0",
	"text":"Follow-‍up Baseline thoracic CT scan should be performed 3–4 months after surgery [V, C] For R0 resected stage I/II thymomas, CT scans should be performed annually for 5 years, then every 2 years [V, C] For stage III/‍IV thymomas, thymic carcinoma, or after R1–2 resection, CT scans should be performed every 6 months for 2 years, then annually thereafter [V, C] Follow-‍up should be continued for 10–15 years [V, C] Participation in clinical trials is recommended"
},
{
	"page":"ENAS5098_9.0.0.0",
	"text":"8.0.0.0 Glossary ACCP American College of Chest Physicians ADOC doxorubicin/‍cisplatin/‍‍vincristine/‍‍cyclophosphamide AE adverse event AHA/ACC American Heart Association/​American College of Cardiology AJCC American Joint Committee on Cancer ALK anaplastic lymphoma kinase AUC area under the curve BSC best supportive care CABG coronary artery bypass grafting CAG coronary angiography CAP cisplatin/‍doxorubicin/‍cyclophosphamide Cap-‍GEM capecitabine/‍‍gemcitabine Carbo-‍Px carboplatin/‍paclitaxel CAV cyclophosphamide/‍‍doxorubicin/‍‍vincristine CEA carcinoembryonic antigen CGA comprehensive geriatric assessment ChT chemotherapy CNS central nervous system CODE cisplatin/‍‍vincristine/‍‍doxorubicin/‍etoposide COPD chronic obstructive pulmonary disease CPET cardiopulmonary exercise testing CPGs Clinical Practice Guidelines CRT chemoradiotherapy CT computed tomography DFS disease-‍free survival DLCO diffusing capacity for carbon monoxide EBUS endobronchial ultrasound ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EMA European Medicines Agency EPP extrapleural pneumonectomy ESMO European Society for Medical Oncology EUS oesophageal ultrasound FDG fluorodeoxyglucose FDG-‍PET 2-‍Fluoro-‍2-‍deoxy-‍D-‍glucose positron emission tomography FEV1 forced expiratory volume in 1 second FISH fluorescence in situ hybridisation FVC forced vital capacity GGO ground glass opacity GOR grade of recommendation IASLC International Association for the Study of Lung Cancer IgG1 immunoglobulin G1 IHC immunohistochemistry ILD interstitial lung disease IMIG International Mesothelioma Interest Group IMRT intensity-‍modulated radiotherapy IPF idiopathic pulmonary fibrosis irRC immune-‍related response criteria ITMIG International Thymic Malignancy Interest Group IV intravenous KPS Karnofsky Performance Status LDCT low-dose computed tomography LDH lactate dehydrogenase LN lymph node LOE level of evidence LVRS lung volume reduction surgery MCBS Magnitude of Clinical Benefit Scale MDT multidisciplinary team MEN1 multiple endocrine neoplasia 1 gene MPM malignant pleural mesothelioma MRI magnetic resonance imaging mTOR mammalian target of rapamycin nab-‍PC albumin-‍bound paclitaxel/‍carboplatin NGS next-‍generation sequencing NOS not otherwise specified NPV negative predictive value NSCC non-‍squamous cell carcinoma NSCLC non-‍small-‍cell lung cancer P/D pleurectomy/‍decortication PCI prophylactic cranial irradiation PCR polymerase chain reaction PD-1 programmed death 1 PD-L1 programmed death ligand 1 PE cisplatin and etoposide PET positron emission tomography PET-CT positron emission tomography-computed tomography PFS progression-‍free survival PORT postoperative radiotherapy ppo predictive postoperative PS performance status QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease R2 resection with macroscopic residual disease RCRI revised cardiac risk index RECIST Response Evaluation Criteria In Solid Tumours RFA radiofrequency ablation RPA recursive partioning analysis RR response rate RT radiotherapy RT-‍PCR reverse transcription polymerase chain reaction RTOG Radiation Therapy Oncology Group RV reserve volume SABR stereotactic ablative radiotherapy SAE serious adverse event SBRT stereotactic body radiotherapy SCC squamous cell carcinoma SCLC small-‍cell lung cancer SRE skeletal-‍related events SRS stereotactic radiosurgery SUVmax maximum standardised uptake values TIA transient ischaemic attack Tis carcinoma in situ TKI tyrosine kinase inhibitor TLC total lung capacity TNM tumour-‍node-‍metastasis TPS tumour proportion score UICC Union for International Cancer Control VAM video-assisted mediastinoscopy VATS video-‍assisted thoracoscopy VEGFR2 vascular endothelial growth factor receptor-2 VIP etoposide/​ifosfamide/​cisplatin VO2 oxygen consumption VO2 max maximal oxygen consumption WBRT whole brain radiotherapy WHO World Health Organization WT wild type"
}
]